References 1. Andreadis A, Gallego ME, Nadal-Ginard B (1987) Generation of protein isoform diversity by alternative splicing: mechanistic and biological implications. Annu Rev Cell Biol 3: 207–242. 2. Modrek B, Lee C (2002) A genomic view of alternative splicing. Nat Genet 30: 13–19. 3. Streuli M, Saito H (1989) Regulation of tissue-specific alternative splicing: exon- specific cis-elements govern the splicing of leukocyte common antigen pre- mRNA. Embo J 8: 787–796. 4. Zuzarte PC, Farrance IK, Simpson PC, Wildeman AG (2000) Tumor cell splice variants of the transcription factor TEF-1 induced by SV40 T-antigen transformation. Biochim Biophys Acta 1517: 82–90. 5. Jiang SW, Desai D, Khan S, Eberhardt NL (2000) Cooperative binding of TEF- 1 to repeated GGAATG-related consensus elements with restricted spatial separation and orientation. DNA Cell Biol 19: 507–514. 6. Kaneko KJ, DePamphilis ML (1998) Regulation of gene expression at the beginning of mammalian development and the TEAD family of transcription factors. Dev Genet 22: 43–55. 7. Stewart AF, Richard CW 3rd, Suzow J, Stephan D, Weremowicz S, et al. (1996) Cloning of human RTEF-1, a transcriptional enhancer factor-1-related gene preferentially expressed in skeletal muscle: evidence for an ancient multigene family. Genomics 37: 68–76. 8. Farrance IK, Ordahl CP (1996) The role of transcription enhancer factor-1 (TEF-1) related proteins in the formation of M-CAT binding complexes in muscle and non-muscle tissues. J Biol Chem 271: 8266–8274. 9. Yasunami M, Suzuki K, Ohkubo H (1996) A novel family of TEA domain- containing transcription factors with distinct spatiotemporal expression patterns. Biochem Biophys Res Commun 228: 365–370. 10. Yockey CE, Smith G, Izumo S, Shimizu N (1996) cDNA cloning and characterization of murine transcriptional enhancer factor-1-related protein 1, a transcription factor that binds to the M-CAT motif. J Biol Chem 271: 3727– 3736. 11. Appukuttan B, McFarland TJ, Davies MH, Atchaneeyasakul LO, Zhang Y, et al. (2007) Identification of novel alternatively spliced isoforms of RTEF-1 within human ocular vascular endothelial cells and murine retina. Invest Ophthalmol Vis Sci 48: 3775–3782. 12. Shie JL, Wu G, Wu J, Liu FF, Laham RJ, et al. (2004) RTEF-1, a novel transcriptional stimulator of vascular endothelial growth factor in hypoxic endothelial cells. J Biol Chem 279: 25010–25016. 13. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, et al. (1996) Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604–4613. 14. Ozaki H, Yu AY, Della N, Ozaki K, Luna JD, et al. (1999) Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 40: 182–189. 15. Levy AP, Levy NS, Wegner S, Goldberg MA (1995) Transcriptional regulation of the rat vascular endothelial growth factor gene by hypoxia. J Biol Chem 270: 13333–13340. 16. Liu Y, Cox SR, Morita T, Kourembanas S (1995) Hypoxia regulates vascular endothelial growth factor gene expression in endothelial cells. Identification of a 59 enhancer. Circ Res 77: 638–643. 17. Robinson CJ, Stringer SE (2001) The splice variants of vascular endothelial growth factor (VEGF) and their receptors. J Cell Sci 114: 853–865. 18. Ryan J. Stephen APS (2006) Retina; Ryan SJ, editor: Elsevier/Mosby. 19. Boyd SR, Zachary I, Chakravarthy U, Allen GJ, Wisdom GB, et al. (2002) Correlation of increased vascular endothelial growth factor with neovascular- ization and permeability in ischemic central vein occlusion. Arch Ophthalmol 120: 1644–1650. 20. Lu M, Adamis AP (2006) Molecular biology of choroidal neovascularization. Ophthalmol Clin North Am 19: 323–334. 21. Husain D, Ambati B, Adamis AP, Miller JW (2002) Mechanisms of age-related macular degeneration. Ophthalmol Clin North Am 15: 87–91. 22. Pourgholami MH, Morris DL (2008) Inhibitors of vascular endothelial growth factor in cancer. Cardiovasc Hematol Agents Med Chem 6: 343–347. 23. Gunther JB, Altaweel MM (2009) Bevacizumab (Avastin) for the treatment of ocular disease. Surv Ophthalmol 54: 372–400. 24. Kallio PJ, Pongratz I, Gradin K, McGuire J, Poellinger L (1997) Activation of hypoxia-inducible factor 1alpha: posttranscriptional regulation and conforma- tional change by recruitment of the Arnt transcription factor. Proc Natl Acad Sci U S A 94: 5667–5672. 25. Connolly DT, Olander JV, Heuvelman D, Nelson R, Monsell R, et al. (1989) Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 264: 20017–20024. 26. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246: 1306– 1309. 27. Keck PJ, Hauser SD, Krivi G, Sanzo K, Warren T, et al. (1989) Vascular permeability factor, an endothelial cell mitogen related to PDGF. Science 246: 1309–1312. 28. Connolly DT, Heuvelman DM, Nelson R, Olander JV, Eppley BL, et al. (1989) Tumor vascular permeability factor stimulates endothelial cell growth and angiogenesis. J Clin Invest 84: 1470–1478. The TEAD4216 Isoform Inhibits VEGF Expression 29. Guerrin M, Scotet E, Malecaze F, Houssaint E, Plouet J (1997) Overexpression of vascular endothelial growth factor induces cell transformation in cooperation with fibroblast growth factor 2. Oncogene 14: 463–471. 30. Ishida A, Murray J, Saito Y, Kanthou C, Benzakour O, et al. (2001) Expression of vascular endothelial growth factor receptors in smooth muscle cells. J Cell Physiol 188: 359–368. 31. Banerjee S, Mehta S, Haque I, Sengupta K, Dhar K, et al. (2008) VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1- VEGFR1-PI3K axis. Biochemistry 47: 3345–3351. 32. Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, et al. (2007) Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 171: 53–67. 33. Alon T, Hemo I, Itin A, Pe’er J, Stone J, et al. (1995) Vascular endothelial growth factor acts as a survival factor for newly formed retinal vessels and has implications for retinopathy of prematurity. Nat Med 1: 1024–1028. 34. Saint-Geniez M, Maharaj AS, Walshe TE, Tucker BA, Sekiyama E, et al. (2008) Endogenous VEGF is required for visual function: evidence for a survival role on muller cells and photoreceptors. PLoS One 3: e3554. 35. Wittko IM, Schanzer A, Kuzmichev A, Schneider FT, Shibuya M, et al. (2009) VEGFR-1 regulates adult olfactory bulb neurogenesis and migration of neural progenitors in the rostral migratory stream in vivo. J Neurosci 29: 8704–8714. 36. Azzouz M, Ralph GS, Storkebaum E, Walmsley LE, Mitrophanous KA, et al. (2004) VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 429: 413–417. 37. Sondell M, Lundborg G, Kanje M (1999) Vascular endothelial growth factor has neurotrophic activity and stimulates axonal outgrowth, enhancing cell survival and Schwann cell proliferation in the peripheral nervous system. J Neurosci 19: 5731–5740. 38. Yamagishi S, Yonekura H, Yamamoto Y, Fujimori H, Sakurai S, et al. (1999) Vascular endothelial growth factor acts as a pericyte mitogen under hypoxic conditions. Lab Invest 79: 501–509. 39. Huh JI, Calvo A, Stafford J, Cheung M, Kumar R, et al. (2005) Inhibition of VEGF receptors significantly impairs mammary cancer growth in C3(1)/Tag transgenic mice through antiangiogenic and non-antiangiogenic mechanisms. Oncogene 24: 790–800. 40. Schoeffner DJ, Matheny SL, Akahane T, Factor V, Berry A, et al. (2005) VEGF contributes to mammary tumor growth in transgenic mice through paracrine and autocrine mechanisms. Lab Invest 85: 608–623. 41. Duker JS, Brown GC (1989) Neovascularization of the optic disc associated with obstruction of the central retinal artery. Ophthalmology 96: 87–91. 42. Miller JW, Adamis AP, Shima DT, D’Amore PA, Moulton RS, et al. (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 145: 574–584. 43. Shima DT, Gougos A, Miller JW, Tolentino M, Robinson G, et al. (1996) Cloning and mRNA expression of vascular endothelial growth factor in ischemic retinas of Macaca fascicularis. Invest Ophthalmol Vis Sci 37: 1334–1340. 44. Kim I, Ryan AM, Rohan R, Amano S, Agular S, et al. (1999) Constitutive expression of VEGF, VEGFR-1, and VEGFR-2 in normal eyes. Invest Ophthalmol Vis Sci 40: 2115–2121. 45. Sheridan CM, Pate S, Hiscott P, Wong D, Pattwell DM, et al. (2009) Expression of hypoxia-inducible factor-1alpha and -2alpha in human choroidal neovascular membranes. Graefes Arch Clin Exp Ophthalmol 247: 1361–1367. 46. Benhaddou A, Keime C, Ye T, Morlon A, Michel I, et al. (2011) Transcription factor TEAD4 regulates expression of Myogenin and the unfolded protein response genes during C2C12 cell differentiation. Cell Death Differ. 47. Gupta M, Kogut P, Davis FJ, Belaguli NS, Schwartz RJ, et al. (2001) Physical interaction between the MADS box of serum response factor and the TEA/ ATTS DNA-binding domain of transcription enhancer factor-1. J Biol Chem 276: 10413–10422. 48. Gupta MP, Amin CS, Gupta M, Hay N, Zak R (1997) Transcription enhancer factor 1 interacts with a basic helix-loop-helix zipper protein, Max, for positive regulation of cardiac alpha-myosin heavy-chain gene expression. Mol Cell Biol 17: 3924–3936. 49. Jin Y, Wu J, Song X, Song Q, Cully BL, et al. (2011) RTEF-1, an Upstream Gene of Hypoxia-inducible Factor-1{alpha}, Accelerates Recovery from Ischemia. J Biol Chem 286: 22699–22705. 50. Teng AC, Kuraitis D, Deeke SA, Ahmadi A, Dugan SG, et al. (2010) IRF2BP2 is a skeletal and cardiac muscle-enriched ischemia-inducible activator of VEGFA expression. FASEB J 24: 4825–4834. 51. Vassilev A, Kaneko KJ, Shu H, Zhao Y, DePamphilis ML (2001) TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes- associated protein localized in the cytoplasm. Genes Dev 15: 1229–1241. 52. Chen L, Chan SW, Zhang X, Walsh M, Lim CJ, et al. (2010) Structural basis of YAP recognition by TEAD4 in the hippo pathway. Genes Dev 24: 290–300. 53. Mahoney WM, Jr., Hong JH, Yaffe MB, Farrance IK (2005) The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members. Biochem J 388: 217–225. PLoS ONE | www.plosone.org 11 June 2012 | Volume 7 | Issue 6 | e31260